Bempegaldesleukin (BEMPEG), a pegylated IL-2 cytokine prodrug, was designed to activate the IL-2 pathway in a controlled and sustained fashion, with the goal of preferentially activating and expanding effector CD8+ T cells and NK cells over immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment (TME)9,10. The gene discussed is CD8A; the disease is neoplasm.